Policy Perspective

Filters

342 results
Comment Letter
Policy Perspective

COGR Letter to FDA Regarding Institutional Review Board Waiver or Alteration of Informed Consent for Minimal Risk Clinical Investigations

Document
Human Subjects
Research Compliance
Policy Perspective
Comment Letter

Joint Association Comment Letter on Emerging Technologies ANPRM

Document
Export Controls
Science & Security
Comment Letter
Policy Perspective

Joint Association Comments on Draft ROI Green Paper

Document
Bayh-Dole & iEdison
Other Intellectual Property & Innovation
Intellectual Property & Innovation
Comment Letter
Policy Perspective

Joint Association Letter to OSP-NIH: RFI on Proposed Provisions for a Draft Data Management and Sharing Policy

Document
Data Management & Public Access
Other Proposal & Award Issues
Proposals & Award Policies
Comment Letter
Policy Perspective
External Resource

Joint Association Memo Requesting Extension from BIS

Document
Export Controls
Science & Security
Comment Letter
Policy Perspective

COGR, AAMC, and ARIO Submit Joint Letter to NIH on Communicating Research Misconduct to NIH, NOT-OD-19-020

Document
Research Integrity & Misconduct
Research Compliance
Comment Letter
Policy Perspective

Joint Response to NIH Registration and Results Reporting Standards for Prospective Basic Science Studies Involving Human Subjects (NOT-OD-18-217)

Document
Human Subjects
Research Compliance
Comment Letter
Policy Perspective

Joint Association Letter on Industrial Hemp

COGR, the Association of American Universities, and the Association of Public and Land-grant Universities sent this letter to congressional leaders to advocate for the inclusion of Senate provisions in the final 2018 Farm Bill that would remove federal regulatory barriers to industrial hemp research. Specifically, they request explicit federal guidance allowing university researchers to obtain, gr
Cannabis/Controlled Substances
Research Compliance
Comment Letter
Policy Perspective

Final Joint Association Comments on Proposed Changes to the NIH Guidelines on Recombinant or Synthetic Nucleic Acid Research

Document
Biosafety & Related Research Issues
Research Compliance
Comment Letter
Policy Perspective

COGR Submits Letter to DEA Regarding Production Quotas for Schedule I & II Controlled Substances

COGR submitted formal comments to the U.S. Drug Enforcement Administration (DEA) regarding the proposed 2019 aggregate production quotas for Schedule I and II controlled substances, with particular attention to marijuana and its derivatives. COGR expressly supports the proposed increase in production quotas for marijuana and tetrahydrocannabinols, seeing this as a constructive move to advance scie
Cannabis/Controlled Substances
Research Compliance